Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07514143 · ClinicalTrials.gov registry record
Bladder EpiCheck Product Development Study
A clinical trial, sponsored by Nucleix.
- Recruiting
- Registry status
- 1,000
- Enrollment target
NCT07514143 is a clinical trial that is actively recruiting participants, run by Nucleix. The registered enrollment target is 1,000 participants.
The verdict
NCT07514143 is actively recruiting participants, sponsored by Nucleix.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
This is a prospective, observational study to support the development of the Bladder EpiCheck kit by collecting urine samples from subjects suspected to have a bladder tumor or under NMIBC surveillance. This is a single visit study. Each subject will sign the informed consent and provide voided urine sample. Demography and, if performed, pathology information will be collected for each subject.
Interventions
- DIAGNOSTIC_TEST Bladder EpiCheck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07514143
The ClinicalTrials.gov registry entry for NCT07514143 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nucleix, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bladder EpiCheck is the first listed.
NCT07514143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07514143 about?
NCT07514143 is a clinical study titled "Bladder EpiCheck Product Development Study". This is a prospective, observational study to support the development of the Bladder EpiCheck kit by collecting urine samples from subjects suspected to have a bladder tumor or under NMIBC surveillance. This is a single visit study. Each subject will sign the informed consent and provide voided uri...
What is the current status of trial NCT07514143?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-09-15. Estimated completion is 2026-12.
What interventions are being tested in trial NCT07514143?
The interventions under investigation include: Bladder EpiCheck (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07514143?
This trial is sponsored by Nucleix, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.